The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

Kidney International

Volumn 93, Issue 6, 2018, Pages 1344-1355

  Barrera Chimal, Jonatan ^a,b   Estrela, Gabriel R ^a   Lechner, Sebastian M ^a   Giraud, Sébastien ^a,c,d   El Moghrabi, Soumaya ^a   Kaaki, Shiem ^a,d   Kolkhof, Peter ^e   Hauet, Thierry ^a,c,d   Jaisser, Frédéric ^a  

^a INSERM   (France)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSITÉ DE POITIERS   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e BAYER AG   (Germany)

Author keywords

inflammation; ischemic injury; macrophage polarization

Indexed keywords

CD11B ANTIGEN; FINERENONE; INTERLEUKIN 4 RECEPTOR; MINERALOCORTICOID RECEPTOR; MYELOID MINERALOCORTICOID RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; CELL SURFACE RECEPTOR; IL4RA PROTEIN, MOUSE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; YORKSHIRE PIG; ACUTE KIDNEY FAILURE; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; FIBROSIS; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PERITONEUM MACROPHAGE; PIG;

ACUTE KIDNEY INJURY; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION MEDIATORS; KIDNEY; MACROPHAGES, PERITONEAL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; PHENOTYPE; RECEPTORS, CELL SURFACE; RECEPTORS, MINERALOCORTICOID; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SUS SCROFA;

EID: 85043484077     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.12.016     Document Type: Article

References (35)

1. Hill, N.R., Fatoba, S.T., Oke, J.L., et al. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One, 11, 2016, e0158765.
2. Chawla, L.S., Eggers, P.W., Star, R.A., et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371 (2014), 58–66.
3. Zuk, A., Bonventre, J.V., Acute kidney injury. Annu Rev Med 67 (2016), 293–307.
4. Barrera-Chimal, J., Pérez-Villalva, R., Rodríguez-Romo, R., et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83 (2013), 93–103.
5. Basile, D.P., Bonventre, J.V., Mehta, R., et al. Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments. J Am Soc Nephrol 27 (2016), 687–697.
6. Jo, S.K., Sung, S.A., Cho, W.Y., et al. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant 21 (2006), 1231–1239.
7. Agarwal, A., Dong, Z., Harris, R., et al. Cellular and molecular mechanisms of AKI. J Am Soc Nephrol 27 (2016), 1288–1299.
8. Lattenist, L., Lechner, S.M., Messaoudi, S., et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension 69 (2017), 870–878.
9. Usher, M.G., Duan, S.Z., Ivaschenko, C.Y., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120 (2010), 3350–3364.
10. Shen, J.Z., Morgan, J., Tesch, G.H., et al. Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages. Endocrinology 157 (2016), 3213–3223.
11. Barrera-Chimal, J., André-Grégoire, G., Nguyen Dinh Cat, A., et al. Benefit of mineralocorticoid receptor antagonism in aki: role of vascular smooth muscle Rac1. J Am Soc Nephrol 28 (2017), 1216–1226.
12. Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604.
13. Van Dyken, S.J., Locksley, R.M., Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol 31 (2013), 317–343.
14. Rossard, L., Favreau, F., Giraud, S., et al. Role of warm ischemia on innate and adaptive responses in a preclinical renal auto-transplanted porcine model. J Transl Med, 11, 2013, 129.
15. Lee, S., Huen, S., Nishio, H., et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 22 (2011), 317–326.
16. Clements, M., Gershenovich, M., Chaber, C., et al. Differential Ly6C expression after renal ischemia-reperfusion identifies unique macrophage populations. J Am Soc Nephrol 27 (2016), 159–170.
17. Vinuesa, E., Hotter, G., Jung, M., et al. Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol 214 (2008), 104–113.
18. Liu, Y.C., Zou, X.B., Chai, Y.F., et al. Macrophage polarization in inflammatory diseases. Int J Biol Sci 10 (2014), 520–529.
19. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat immunol 11 (2010), 889–896.
20. Meng, X.M., Tang, P.M., Li, J., et al. Macrophage phenotype in kidney injury and repair. Kidney Dis (Basel) 1 (2015), 138–146.
21. Smith, T.D., Tse, M.J., Read, E.L., et al. Regulation of macrophage polarization and plasticity by complex activation signals. Integr Biol (Camb) 8 (2016), 946–955.
22. Ko, G.J., Boo, C.S., Jo, S.K., et al. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 23 (2008), 842–852.
23. Zhang, M.Z., Yao, B., Yang, S., et al. CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest 122 (2012), 4519–4532.
24. Zhang, M.Z., Wang, X., Wang, Y., et al. IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int 91 (2017), 375–386.
25. Lim, H.Y., Müller, N., Herold, M.J., et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122 (2007), 47–53.
26. Frieler, R.A., Meng, H., Duan, S.Z., et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42 (2011), 179–185.
27. Huang, L.L., Nikolic-Paterson, D.J., Han, Y., et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25 (2014), 2231–2240.
28. Giraud, S., Favreau, F., Chatauret, N., et al. Contribution of large pig for renal ischemia-reperfusion and transplantation studies: the preclinical model. J Biomed Biotechnol, 2011, 2011, 532127.
29. Barba-Navarro, R., Tapia-Silva, M., Garza-Garcia, C., et al. The Effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial. Am J Kidney Dis 69 (2017), 192–199.
30. Bar-Nur, D., Jaber, B.L., Mineralocorticoid receptor blockade for prevention of acute kidney injury: an elusive target. Am J Kidney Dis 69 (2017), 166–168.
31. Juurlink, D.N., Mamdani, M.M., Lee, D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004), 543–551.
32. Lepage, L., Desforges, K., Lafrance, J.P., New drugs to prevent and treat hyperkalemia. Curr Opin Nephrol Hypertens 25 (2016), 524–528.
33. Berger, S., Wolfer, D.P., Selbach, O., et al. Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA 103 (2006), 195–200.
34. Clausen, B.E., Burkhardt, C., Reith, W., et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8 (1999), 265–277.
35. Wendling, O., Bornert, J.M., Chambon, P., et al. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 47 (2009), 14–18.